To evaluate the therapeutic efficacy of CAR20-T cells in an immunocompetent mouse model, murine (m)CAR-T cells were engineered using retroviral vectors (RV) with the CAR20 linked to the murine CD28 and CD3ζ intracellular signaling domains (Fig. 2A). We have previously shown that NAP-armed CAR-T cells improve therapeutic efficacy in several murine tumor models compared to conventional CAR-T cells [27]. This evidence concerns the gene CD247 and neoplasm.